IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0597378
(2005-01-21)
|
등록번호 |
US-8147825
(2012-04-03)
|
국제출원번호 |
PCT/US2005/001581
(2005-01-21)
|
§371/§102 date |
20080821
(20080821)
|
국제공개번호 |
WO2005/069916
(2005-08-04)
|
발명자
/ 주소 |
- Hsia, Sung Lan
- Narain, Niven Rajin
- Li, Jie
- Russell, Kathryn J.
- Woan, Karrune V.
- Persaud, Indushekhar
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
5 인용 특허 :
97 |
초록
▼
Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation o
Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.
대표청구항
▼
1. A method of treating melanoma in a subject, comprising topically applying for at least 30 days a 1 to 15% w/w composition of Coenzyme Q10 to the site of the melanoma in an amount effective to reduce the growth of the melanoma. 2. The method of claim 1, wherein the composition comprising Coenzyme
1. A method of treating melanoma in a subject, comprising topically applying for at least 30 days a 1 to 15% w/w composition of Coenzyme Q10 to the site of the melanoma in an amount effective to reduce the growth of the melanoma. 2. The method of claim 1, wherein the composition comprising Coenzyme Q10 is administered with an additional anti-cancer agent. 3. The method of claim 2, wherein the additional agent is an anti-angiogenic agent. 4. The method of claim 2, wherein the additional anti-cancer agent is co-administered with the composition comprising Coenzyme Q10 to the subject. 5. The method of claim 2, wherein administration of the additional anti-cancer agent precedes administration of the composition comprising Coenzyme Q10 to the subject. 6. The method of claim 2, wherein administration of the additional anti-cancer agent follows administration of the composition comprising Coenzyme Q10 to the subject. 7. The method of claim 1, wherein the additional anti-cancer agent is a chemotherapeutic agent. 8. The method of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, taxanes, busulfan, methotrexate, daunorubicin, doxorubicin, melphalan, and cladribine. 9. The method of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of vincristine, vinblastine, chlorambucil, tamoxifen, taxol, camptothecin, actinomycin-D, mitomycin C, and combretastatin. 10. The method of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, etoposide, verapamil, and podophyllotoxin. 11. The method of claim 7, wherein the chemotherapeutic agent is 5-fluorouracil. 12. The method of claim 1, wherein the subject is human. 13. The method of claim 1, wherein the composition comprising Coenzyme Q10 is formulated as a topical cream. 14. The method of claim 1, wherein the composition comprising Coenzyme Q10 is liposomal. 15. The method of claim 1, wherein the composition comprises 1% to 10% w/w of Coenzyme Q10. 16. The method of claim 1, wherein the composition comprises 1% to 5% w/w of Coenzyme Q10. 17. The method of claim 1, wherein treatment results in an increase in apoptosis of melanoma cells in the subject. 18. The method of claim 1, wherein treatment results in inhibition of melanoma-mediated angiogenesis in the subject. 19. A method of treating melanoma in a subject, comprising topically applying for at least 30 days a 1 to 15% w/w composition of Coenzyme Q10 in an amount of no more than 4.0 mg per kg of body weight to the site of the melanoma effective to reduce the growth of the melanoma.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.